Please assess the completion status of the following clinical trial:

Trial Title: Study of Mirogabalin for Central Neuropathic Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Spinal cord injury (SCI) due to trauma~* American Spinal Injury Association impairment scale A, B, C, or D~Exclusion Criteria:~* Other severe pain at screening or randomization, unrelated to central neuropathic pain after SCI, that may confound the assessment of central neuropathic pain after SCI~* Neurologic disorders at screening or randomization, unrelated to central neuropathic pain after SCI, that may confound the assessment of central neuropathic pain after SCI~* Major psychiatric disorders within 1 year prior to screening

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mirogabalin (Type: EXPERIMENTAL): The patients with creatinine clearance (CLcr) ≥ 60 mL/min: Mirogabalin 20 mg or 30 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks maintenance dose.~The patients with creatinine clearance (CLcr) 30 to \< 60 mL/min: Mirogabalin 10 mg or 15 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks maintenance dose
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (14-weeks)

Based on this trial design, predict the completion outcome and termination type (if applicable).